Piritrexim

• Description:

  Piritrexim (BW 301U) is a potent dihydrofolate reductase (DHFR) inhibitor against Pneumocystis carinii and Toxoplasma gondii, with IC50 values of 0.038 and 0.011 μM, respectively. Piritrexim can be used for acquired immune deficiency syndrome (AIDS) research. Piritrexim also is an anticancer agent[1].

• Product Name Alternative:

  BW 301U; NSC 351521

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Dihydrofolate reductase (DHFR)

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Infection

• Assay Protocol:

  https://www.medchemexpress.com/piritrexim.html

• Purity:

  99.68

• Smiles:

  CC1=C(CC2=C(C=CC(OC)=C2)OC)C=NC3=NC(N)=NC(N)=C13

• Molecular Formula:

  C17H19N5O2

• Molecular Weight:

  325.37

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Rosowsky A, et al. 2,4-Diaminothieno[2,3-d]pyrimidine analogues of trimetrexate and piritrexim as potential inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase. J Med Chem. 1993 Oct 15;36 (21) :3103-12. |[2]Zink M, et al. Structural variations of piritrexim, a lipophilic inhibitor of human dihydrofolate reductase: synthesis, antitumor activity and molecular modeling investigations. Eur J Med Chem. 2004 Dec;39 (12) :1079-88.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• CAS Number:

  [72732-56-0]